Stock PLRX PLIANT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
13.81 USD 0.00% Intraday chart for Pliant Therapeutics, Inc. -1.22% -23.74%
May. 07 Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating MT
May. 07 RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating
MT
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
GL
RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk
MT
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GL
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Pliant Therapeutics to Participate in Upcoming Investor Events
GL
Pliant Therapeutics to Participate in Upcoming Investor Events
AQ
Pliant Therapeutics to Participate in Upcoming Investor Events
GL
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
GL
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
AQ
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
CI
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
GL
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
AQ
RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept
MT
Pliant Therapeutics : March 2024 Corporate Presentation
PU
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk
MT
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
GL
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
AQ
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLRX Stock
  4. News Pliant Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW